NEW YORK (GenomeWeb) – Rosetta Genomics today announced a deal to sell tests from Admera Health to oncologists and pathologists.

South Plainfield, NJ-based Admera is a molecular diagnostics spinoff of the clinical services unit of genomics contract research organization GeneWiz. As part of the deal, Rosetta will market Admera's tests, including PGxOne, which predicts how patients will respond to drugs based on their genetic profiles. Rosetta also will make available Admera's EGFR and KRAS clinical sequencing service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.